ALTS - ALT5 Sigma Corp

1.38
-0.020   -1.449%

Share volume: 989,301
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$1.40
-0.02
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 42%
Liquidity 31%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.82%
1 Month
-2.82%
3 Months
-6.76%
6 Months
-66.99%
1 Year
-70.89%
2 Year
-77.83%
Key data
Stock price
$1.38
P/E Ratio 
N/A
DAY RANGE
$1.35 - $1.46
EPS 
-$0.67
52 WEEK RANGE
$1.08 - $10.95
52 WEEK CHANGE
-$66.26
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
122.609 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-02-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$2,498,587
AVERAGE 30 VOLUME 
$2,584,455
Company detail
CEO: Antonios Isaac
Region: US
Website: janone.com
Employees: 170
IPO year: 1991
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

JanOne Inc. focuses on identifying, acquiring, licensing, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease.

Recent news